Exact Sciences(EXAS) Zacks Investment Research·2024-05-08 23:06分组1 - Exact Sciences reported a quarterly loss of 0.42 per share a year ago [1] - The company achieved revenues of 602.45 million year-over-year [1] - Over the last four quarters, Exact Sciences has surpassed consensus EPS estimates three times and revenue estimates four times [1] 分组2 - Exact Sciences shares have declined approximately 17% since the beginning of the year, contrasting with the S&P 500's gain of 8.8% [2] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [2] - The current consensus EPS estimate for the next quarter is -698.32 million, and for the current fiscal year, it is -2.83 billion [4] 分组3 - The Medical - Biomedical and Genetics industry, to which Exact Sciences belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook [4] - The performance of Exact Sciences may be influenced by the overall industry outlook, as the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [4] - Another company in the same industry, Allogene Therapeutics, is expected to report results for the quarter ended March 2024 on May 13 [4]